Phase II trial of paclitaxel plus doxorubicin plus carboplatin in patients with intermediate risk, high risk, or recurrent endometrial carcinoma No significant financial relationships to disclose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results